VZV gE Specific Neutra™ Antibody Products

Product list

Accelerate Your Research and Development!

Are you currently facing challenges in achieving optimal sensitivity and specificity in Varicella-Zoster Virus (VZV) diagnostic assays, or struggling to find high-affinity reagents essential for robust vaccine quality control? Our VZV gE-Specific Neutra™ Antibody Products help you accelerate therapeutic and vaccine development and obtain the precise, high-titer neutralizing reagents required to reliably quantify viral antigen levels and study host-pathogen interactions through advanced recombinant antibody engineering and rigorous functional validation.

Contact our team to get an inquiry now!

Introduction of VZV gE

Varicella-Zoster Virus (VZV), a member of the Herpesviridae family, causes chickenpox (primary infection) and shingles (upon reactivation). VZV Glycoprotein E (gE) is the most abundant glycoprotein on the virion envelope and infected cell surfaces, and is essential for the viral lifecycle.

Structure and Function: VZV gE primarily forms a heterodimer with glycoprotein I (gI) (the gE-gI complex), which is central to critical viral processes:

Viral Entry and Fusion: The gE-gI complex facilitates the fusion of the viral envelope with the host cell membrane, initiating infection.
Cell-to-Cell Spread: gE mediates VZV's highly efficient cell-to-cell transmission, allowing the virus to evade host immunity.
Immune Modulation: gE interacts with the host immune system, including binding to the mannose-6-phosphate receptor (M6PR).
Clinical Relevance: VZV gE is the dominant antigen targeted by the humoral immune response and is the core component of the successful recombinant shingles vaccine.

Antibodies against gE's key epitopes are highly effective at neutralizing the virus, making gE an essential benchmark for VZV research.

Fig.1 Picture of the native structure and associated activities of VZV gE. (OA Literature) Fig.1 Characterization of VZV gE constructs and anti-gE Fabs.¹

Antibodies Against VZV gE

Antibodies specific to VZV gE are high-value reagents due to the protein's importance in both viral pathology and clinical prevention. The primary application of these antibodies is driven by their ability to inhibit or neutralize VZV infectivity.

Applications of Anti-VZV gE Antibodies:

Viral Neutralization Assays: The hallmark application, where anti-gE antibodies are used to directly block VZV infectivity in cell culture, serving as a gold standard for assessing immune protection.
ELISA and Immunosorbent Assays: For high-throughput screening and quantification of VZV gE in recombinant protein preparations, vaccine formulations, and clinical samples.
Western Blotting (WB): To confirm the presence and molecular weight of VZV gE in infected cell lysates or purified protein stocks, ensuring antigen integrity.
Immunohistochemistry (IHC) and Immunofluorescence (IF): To visualize VZV gE expression and distribution on the surface of infected cells or within tissue samples, allowing for detailed study of viral spread.

The rigorous development of antibodies with high specificity to the functional epitopes of gE is critical for developing next-generation VZV diagnostics and therapeutics.

Why Choose Us?

Choosing Creative Biolabs for VZV gE-Specific Neutra™ Antibodies means partnering with specialists in high-fidelity viral reagents. Our two decades of expertise guarantee reproducible and superior product performance.

Key Advantages of Creative Biolabs' Neutra™ Products:

Verified Neutralizing Efficacy: Each lot is functionally validated in VZV neutralization assays, confirming biological activity beyond simple binding.
Exceptional Epitope Specificity: Antibodies target key functional domains of VZV gE, ensuring high specificity to the clinically relevant antigen and minimizing cross-reactivity.
Comprehensive Quality Control: We utilize advanced analytical techniques, including surface plasmon resonance (SPR) and mass spectrometry, for affinity measurement and purity verification.
Supported by Proven Success: Our reagents have been utilized in numerous successful external and internal studies, supporting novel diagnostic platforms and demonstrating high performance.

FAQs

Q: What is the primary functional advantage of using a VZV gE-specific antibody compared to one targeting a less abundant glycoprotein?

A: Targeting gE provides a major advantage as it is the most abundant and immunodominant envelope protein. Anti-gE antibodies are highly likely to demonstrate strong neutralizing activity by efficiently blocking the most prevalent viral surface feature necessary for cell entry and spread, offering a more robust functional outcome.

Q: In which assay formats do these high-affinity reagents show the best performance for VZV detection?

A: These reagents are optimized for high performance in quantitative immunoassays. They excel in sandwich ELISA for antigen quantification, highly sensitive immunofluorescence assays, and are the gold standard in plaque reduction neutralization tests (PRNT) for functional analysis.

Q: Are these antibodies suitable for distinguishing between VZV infection and vaccine-induced immunity?

A: While anti-gE antibodies are central to both natural infection and the gE-only recombinant subunit vaccine response, highly specific reagents are crucial. They are ideal for standardizing the quantification of gE-specific antibody titers, which is necessary for comparisons, though full interpretation often requires an antigen panel or clinical data.

Q: How can I ensure the antibody will function optimally in my specific cell culture neutralization system?

A: For optimal performance, a comprehensive titration using your specific VZV strain and target cell line is recommended. Critical parameters include optimizing antibody concentration, viral multiplicity of infection (MOI), and incubation period. Always start with the provided functional data sheet as a strong foundation.

Q: What critical quality control measure should I look for when evaluating alternatives to ensure superior performance?

A: Beyond basic binding affinity, the most critical measure is functional validation. Look for data demonstrating a low half-maximal inhibitory concentration (IC₅₀) or high neutralizing titer (NT₅₀) in a standardized viral inhibition assay, as this confirms the antibody can effectively neutralize the virus.

Creative Biolabs is dedicated to advancing VZV research and vaccine development by providing best-in-class VZV gE-Specific Neutra™ Antibody Products. Leveraging our deep scientific knowledge, we deliver high-purity, functionally validated reagents that ensure the specificity and reliability your critical projects demand.

Access the Creative Biolabs Edge – Request Your Quote Now

REFERENCE

Harshbarger, Wayne D et al. "Structures of the Varicella Zoster Virus Glycoprotein E and Epitope Mapping of Vaccine-Elicited Antibodies." Vaccines vol. 12,10 1111. 27 Sep. 2024, Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/vaccines12101111

Show More Close